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Abstract
Ion channels have recently attracted attention as potential mediators of skin disease. Here,
we explored the consequences of genetically encoded induction of the cell volume-regulat-
ing Ca2+-activated KCa3.1 channel (Kcnn4) for murine epidermal homeostasis. Doxycy-
cline-treated mice harboring the KCa3.1+-transgene under the control of the reverse
tetracycline-sensitive transactivator (rtTA) showed 800-fold channel overexpression above
basal levels in the skin and solid KCa3.1-currents in keratinocytes. This overexpression
resulted in epidermal spongiosis, progressive epidermal hyperplasia and hyperkeratosis,
itch and ulcers. The condition was accompanied by production of the pro-proliferative and
pro-inflammatory cytokines, IL-β1 (60-fold), IL-6 (33-fold), and TNFα (26-fold) in the skin.
Treatment of mice with the KCa3.1-selective blocker, Senicapoc, significantly suppressed
spongiosis and hyperplasia, as well as induction of IL-β1 (-88%) and IL-6 (-90%). In conclu-
sion, KCa3.1-induction in the epidermis caused expression of pro-proliferative cytokines
leading to spongiosis, hyperplasia and hyperkeratosis. This skin condition resembles
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pathological features of eczematous dermatitis and identifies KCa3.1 as a regulator of epi-
dermal homeostasis and spongiosis, and as a potential therapeutic target.
Introduction
Ion channels have long been known to contribute to the pathophysiology of inflammatory,
autoimmune [1], and proliferative diseases [2–4]. More recently, several calcium-permeable
channels of the transient receptor potential family (TRP) and potassium channels have been
found to be involved in skin conditions, such as melanoma [5], psoriasis [6], atopic dermatitis
[7], Olmsted syndrome [8], and rosacea [9–11], suggesting the respective channels as potential
treatment targets.
Although it has never been experimentally demonstrated to be present in the epidermis,
one of the K+ channels proposed to be a skin ion channels is the intermediate-conductance
Ca2+–activated K+ channel, KCa3.1, encoded by the KCNN4-gene [12–14]. Its calmodulin
mediated activation produces K+ efflux and membrane hyperpolarization, thus serving
well-known biological functions in other tissues, such as erythrocyte volume decrease
[15,16], hyperpolarization-driven Ca2+-influx, proliferation and cytokine production in T-
cells [1, 17], migration and activation of macrophages/microglia [18,19], Cl−and H2O secre-
tion in epithelia [20,21], as well as endothelium-derived hyperpolarization-mediated vaso-
dilation [22,23].
From the pathophysiological perspective, KCa3.1 induction has been implicated in several
diseases states characterized by excessive cell proliferation and inflammation (For recent in-
depth reviews of KCa3.1 in health and as drug target in disease see [1,2, 24]. For instance,
induction of KCa3.1 was shown to regulate the phenotypic switch of fibroblasts and smooth
muscle cells towards a dedifferentiated proliferative phenotype that promoted pathological
organ remodeling in the lung, heart, and kidneys [25–30], as well as arterial neointima forma-
tion [18, 31,32]. In addition, high expression of KCa3.1 has been considered a marker of
tumor progression for some cancers [3, 33,34].
KCa3.1, therefore, can be viewed as a possible driver of disease, and several small molecule
inhibitors for this therapeutically attractive target have been developed and tested in pre-clini-
cal animal models [35,36]. The inhibitor, ICA-17043 (Senicapoc), initially intended for the
treatment of sickle cell anemia, has been found clinically safe [37] and is currently being con-
sidered for drug repurposing for stroke and Alzheimer’s disease, two conditions in which
KCa3.1 contributes to the pathophysiology [19, 38].
However, concerning the skin, the physiological role of KCa3.1 and its pathophysiological
significance for human skin disease is largely unexplored. So far, KCa3.1 protein expression
and/or mRNA message have been found in rat epidermis [39], in human keratinocytes and
melonama [5], where pharmacological inhibition of KCa3.1 has anti-proliferative efficacy in
vitro. Yet, the role of KCa3.1 in the healthy or diseased epidermis remains elusive. Here, we
hypothesized that epidermal KCa3.1, as a channel that controls cell volume, proliferation and
chloride and water-secretion, is a regulator of epidermal homeostasis.
To test the hypothesis, we generated conditional KCa3.1-overexpressor mice (KCa3.1+)
that harbor a murine Kcnn4-transgene under the control of a tetracycline response element
(TRE) together with a rtTA-transgene [40] for DOX-inducible Kcnn4-transgene expression
specifically in epithelia including the epidermis (Fig 1A) and found that KCa3.1-induction
causes eczematous dermatitis characterized by intra-epidermal edema (spongiosis), epidermal
hyperplasia and hyperkeratosis, severe itch, and ulcers.
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Material & methods
Transgenic mice
Our TRE-TgKcnn4 mice were generated at Unitech Co., Ltd. (Chiba, Japan). Briefly, a tetracy-
cline-regulated Kcnn4 expression construct was generated by subcloning PCR-amplified
Fig 1. A) Plasmid construct for generation of Kcnn4 transgenic mice and induction (gene product: KCa3.1) in epithelial tissues. B) Induction of KCa3.1 transgene
expression by 2-weeks DOX-treatment over basal levels in various tissues as measured by qRT-PCR. Data (% of control (-DOX)) are given as means +/- SEM; �P<0.01,
Student T test; Br, brain (DOX, n = 4; -DOX, n = 2); Int, small intestine (DOX, n = 7; -DOX, n = 6); Lu, lung (DOX, n = 11; -DOX, n = 10); Sk, skin (DOX, n = 7; -DOX,
n = 6); Skin-Epi, skin epidermis (DOX, n = 7; -DOX, n = 2); Sp, spleen (DOX, n = 4; -DOX, n = 2). C) Whole-cell patch-clamp on freshly isolated keratinocytes from tail
skin. Representative recordings of large KCa3.1 currents in keratinocytes (+DOX) from DOX-treated mice and currents in keratinocytes from untreated Ctrls (-DOX).
Note: For an additional recording of small KCa3.1 currents in a keratinocyte from untreated Ctrl see S1A Fig. Inhibition of KCa3.1 currents by RA-2 at 1 μM. Inset:
Summary data of KCa3.1-outward currents at a clamp potential of 0 mV. Data (pA/pF) are given as means +/- SEM (-DOX, n = 4; DOX n = 5); �P<0.01, Student’s T
test. D). Immune histochemical detection of KCa3.1 protein in the epidermis of DOX-treated mice (+DOX, n = 2) and an untreated mouse (-DOX): panels a and b with
primary AB against KCa3.1; c and d without primary AB against KCa3.1. Inserts: 3 x zoom into epidermal layer.
https://doi.org/10.1371/journal.pone.0222619.g001
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cDNA encoding the open reading frame of murine Kcnn4 (gene ID16534)) into the pTRE--
Tight expression vector (Clontech). The construct was verified by sequencing. The pTRE--
Tight vector construct was cleaved with the restriction enzyme and injected into pronuclei of
fertilized mouse oocytes of the C57BL/6J strain. The putative TRE-TgKcnn4 founders obtained
were genotyped by PCR with primers specific for the murine Kcnn4 sequence. Two founders
were crossed with wild type C57BL/6J mice to establish the F1 generation. One line was inbred
over 2–3 generations and then crossed with B6.Cg-Gt(ROSA)26Sortm1(rtTA�M2)Jae/J + [40].
Routine genotyping was performed by using DNA from tail tips and PCR primers (see
Table 1) and the SuperHotTaq Master mix (BIORON GMBH, Germany); cycle program: 94˚C
for 2 min, 35 cycles 94˚C for 20 sec, 56˚C for 30 sec, 72˚C for 30 sec, and cooling to 10˚C. PCR
products were separated by gel electrophoresis (1.5% agarose). Pups of both sex being hemizy-
gous for both transgenes were used for later experimentation (age range 8–20 weeks). All
transgenic mice were generated and maintained within a specific pathogen free (SPF) barrier
facility of Aragonese Center for Biomedical Research according to local and national
regulations.
For transgene-induction over 1 or 2 weeks, doxycycline (DOX, Sigma) was added to the
drinking water (1mg/ml) and water intake was monitored. Senicapoc was synthesized in-
house as previously described [41]. Senicapoc-medicated chow was prepared to administer a
dose of 30 mg/kg/day during the entire DOX-treatment until sacrifice. We did not include a
group of control mice (-DOX) treated with senicapoc since even higher doses of senicapoc had
previously been found to be safe in mice when administered for 3 months [41]. The Photo-
and video-documentation was routinely performed at the day of or the day prior to sacrifice.
Organs and blood were collected after CO2 suffocation and stored on dry ice or fixed in neu-
tral-buffered formaldehyde (4%) until further processing. All procedures were approved by
the Ethics Committee for Animal Research of the University of Zaragoza (PI27/13; PI28/12;
PI37/13/16; PI32/15) and in accordance with the ARRIVE guidelines.
Isolation of epidermis and epidermal keratinocyte
Tails were sterilized by short immersion in 90% ethanol and then stored in MEM-Earle with
20 mM HEPES until further processing. For separation of the skin from the underlying tissue,
the skin was carefully cut open and removed from the base to the tip of the tail and cut into
approximately 0.5 cm2 large pieces. Thereafter, pieces floated on a 0.25% trypsin/phosphate-
buffered solution (PBS) overnight. For keratinocyte isolation, epidermis was carefully sepa-
rated from the rest of skin (consisting mainly of remaining epidermal hair follicles, dermis,
fatty and connective tissue) and was cut into small pieces using a scalpel. Keratinocytes were
Table 1. Primers for PCR and qRT-PCR.
Gene Forward Reverse Accesion No.
EREG TGGGTCTTGACGCTGCTTTGTCTA AAGCAGTAGCCGTCCATGTCAGAA NM_007950.2
GAPDH AGGGAGATGCTCAGTGTTGG CAATGAATACGGCTACAGCAAC NM_001289726.1
HB-EGF CAGGACTTGGAAGGGACAGA CCCTAACCCCTTTCCTTTCTT NM_010415.2
HGF CATTGGTAAAGGAGGCAGCTATAAA GGATTTCGACAGTAGTTTTCCTGTAGG NM_001289460.2
IL-1β TGCCACCTTTTGACAGTGATG AAGGTCCACGGGAAAGACAC NM_008361.4
IL-6 TCTGCAAGAGACTTCCATCCA AGTCTCCTCTCCGGACTTGT NM_031168.2
TGFα CTGTGTGCTGATCCACTGCT CAAGCAGTCCTTCCCTTCAG NM_031199.4
TNFα CCCACGTCGTAGCAAACCAC GCAGCCTTGTCCCTTGAAGA NM_013693.3
KCa3.1 GTCTGCTGCACAGCTCTCCT TCCTTCCTTCGAGTGTGCTT NM_008433.4
https://doi.org/10.1371/journal.pone.0222619.t001
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dispersed by repeated passing through the tip of a cell culture pipette, seeded on coverslips in
MEM Earle supplemented with 10% calf serum, and used for patch-clamp experiments within
the next 3 hrs.
Patch-clamp electrophysiology
Ca2+-activated K+ currents in murine keratinocytes were measured in the whole-cell configu-
ration using an EPC10-USB amplifier (HEKA, Electronics, Lambrecht-Pfalz, Germany) and a
pipette solution (intracellular) containing 1 μM Ca2+ free for channel activation (in mM): 140
KCl, 1 MgCl2, 2 EGTA, 1.71 CaCl2 (1 μM [Ca2+]free) and 5 HEPES (adjusted to pH 7.2 with
KOH). The free Ca2+ concentration was calculated with the MaxChelator program (https://
somapp.ucdmc.ucdavis.edu/pharmacology/bers/maxchelator/webmaxc/webmaxcS.htm). The
bath solution contained (in mM): 140 NaCl, 5 KCl, 1 MgSO4, 1 CaCl2, 10 glucose and 10
HEPES (adjusted to pH 7.4 with NaOH). For KCa3.1 inhibition, we applied 1,3-Phenylenebis
(methylene)bis(3-fluoro-4-hydroxybenzoate (RA-2) at a concentration of 1 μM (n = 2, experi-
ments). Data acquisition and analysis was done with the Patch-Master program (HEKA).
Ohmic leak conductance of up to 1 nS was subtracted where appropriate. We quantified out-
ward currents at a potential of 0 mV. Membrane capacitance was 6 +/- 1 pF (n = 4) in kerati-
nocytes from Dox-treated mice and 7 +/- 2 pF (n = 5) in keratinocytes from non-treated mice.
Histology
Samples were fixed in 4% formaldehyde for at least 24 hrs and then transferred to 60% ethanol.
Thereafter samples were imbedded in paraffin and cut into 4 μm-thick sections. Sections were
stained with hematoxylin and eosin. Scoring: For quantifying and comparing the skin pathol-
ogy, skin sections were scored for grade of hyperplasia, and hyperkeratosis by a pathologist
(MM) and for grade of intra-epidermal edema by two investigators (RK/KLH), independently
and in a blinded fashion. We used the following in-house developed scoring system: Mild:
�0.5<1; Moderate:�1<2; Severe:�2. Individual scores for intra-epidermal edema did not
vary by more than 0.5 and were averaged.
Immunohistochemistry and TUNEL assay
For KCa3.1, tissue samples were fixed in 4% neutral buffered formaldehyde solution and
embedded in paraffin. 2.5 μm-thick sections were cut with a rotation microtome (Leica
RM2255). Slides were air dried at 37˚C overnight, were de-paraffinized in xylene for 10 min,
and then rehydrated. After rehydration, epitope retrieval was carried out using the PT Link
(Dako) at 95˚C for 20 min in a high pH buffer (Dako Antigen retrieval, high pH). Endogenous
peroxidase was blocked using the EnVision FLEX Peroxidase-Blocking kit followed by two
washes for 5 min each (Dako wash buffer). Sections were incubated for 60 min with a rabbit
anti-KCNN4 primary antibody (AV35098, Sigma-Aldrich) at 1/2000 dilution followed by two
washes. Signal amplification was done using the ImmPRESS™ Excel Amplified HRP Polymer
Staining Kit (Vector Laboratories). After 3 wash steps (Dako wash buffer, 5 min each). Sections
were incubated with 3,3’-diaminobenzidine (DAB) for 10 min and counterstained with
hematoxylin.
Proliferating cell nuclear antigen (PCNA) and Caspase 3 (CASP3): 5 μm-thick tissue sec-
tions were placed on silanated slides. After de-paraffinization, endogenous peroxidase was
quenched by immersing the samples in methanol containing 0.03% hydrogen peroxide. Heat
antigen retrieval was performed in pH 6.5 10 μM citrate-based buffered solution (Dako). In
order to prevent non-specific binding, samples were incubated for 2 h with Protein Block
(Dako). Samples were incubated overnight at 4˚C with mouse and rabbit monoclonal
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antibodies against PCNA (Cell Signaling, 1:100) and Cleaved-CASP3 (Calbiochem, 1:100),
respectively, followed by incubation with an anti-mouse or anti-rabbit polymer-based Ig cou-
pled with peroxidase (Cell Signaling) for 30 min at RT. Then, sections were incubated with
3,3’-diaminobenzidine (DAB) and counterstained with hematoxylin, and studied under an
Olympus BX-61 microscope.
Apoptosis was determined by using the TUNEL (Terminal deoxynucleotide transferase
mediated X-dUTP nick end labeling) assay. 5 μm-thick sections were de-paraffinized and
rehydrated. Then, sections were treated with Proteinase K (20 μg ml–1, 15 min, at RT) and
rinsed twice with phosphate buffered saline (PBS). For detection of apoptotic nuclei, sections
were incubated for 1 hrs at 37˚C in the dark with the in situ Cell Death Detection Kit (Roche)
according to the manufacturer’s instructions. After two washes with PBS, sections were
mounted in ProLong1 with DAPI (Life technologies). Fluorescence-microscopy was per-
formed with an Olympus BX-61 epi-fluorescence microscope equipped with filter sets for fluo-
rescence microscopy: ultraviolet (UV, 365 nm, exciting filter UG-1) and blue (450–490 nm,
exciting filter BP 490). Photographs were taken with a digital Olympus CCD DP70 camera.
RNA isolation, reverse transcription, and quantitative RT-PCR
Depilated skin of the neck and other organs were placed into 1 ml TriReagent (Sigma, Saint
Louis, Missouri, USA) and stored at -80˚C. Samples were homogenized with a T10 basic
ULTRA-TURRAX (IKA, Staufen, Germany) at 4˚C.
Total RNA was isolated with the TriReagent following the manufacturer’s protocol, and fur-
ther purified using RNA Clean-up and Concentration-Micro-Elute kit (Norgen Biotek, Thor-
old, Canada). Genomic DNA was digested using the Ambion DNA-free kit (Invitrogen,
Carlsbad, California, USA). Quantity and purity of extracted RNA were determined by spec-
trophotometry (NanoDrop1000, Thermofisher, Waltham, MA) and stored at −80˚C for later
use. Integrity of RNA samples and successful digestion of genomic DNA were verified by gel
electrophoresis. Reverse transcription was performed with 600 ng of total RNA by using the
Super Script III reverse transcriptase (Invitrogen, Carlsbad, California, USA) and random hex-
amers following the manufacturer’s protocol.
cDNA obtained from 10 ng of total RNA was amplified in triplicates using the SYBR Select
Master Mix and a StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, Cali-
fornia, USA) using the following cycle protocol: 95˚C, 15 s and 60˚C, 60 s repeated for 40
cycles. As final step, a melting curve analysis was carried out to verify correct amplification.
The primers are given in Table 1. Data were analyzed with LinReg PCR software and gene
expression levels relative to Gapdh expression as reference gene and normalized to control
were calculated using the formula: % of Gapdh = EfficiencyCq(Gapdh)−Cq(GOI)x100. The values
were used to calculate ratio values (DOX/-DOX; Senicapoc/Ctrl) given in graphs.
LC-MS analysis
A 10 mM stock solution of Senicapoc (from in-house organic synthesis) was prepared by dis-
solving 6.4 mg Senicapoc in 2 ml acetonitrile. Working standard solutions were obtained by
diluting the stock solution with acetonitrile.
Preparation of plasma samples: Commercial SPE cartridges (Hypersep C18, 100 mg, 1 ml)
were purchased from Thermo Scientific (Houston, TX, U.S.A). Before extraction, cartridges
were conditioned with acetonitrile, 2 × 1 ml, followed by water, 2-times × 1 ml. After loading
the SPE cartridges with plasma samples, they were washed successively with 1 ml each of 20%
and 40% acetonitrile in water followed by elution with 2 ml of acetonitrile. Elute fractions were
collected and evaporated to dryness, under a constant flow of air, using a PIERCE Reacti-
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VapTM III evaporator (PIERCE, Il, USA). The residues were reconstituted using 200 μl aceto-
nitrile and were used for LC-MS analysis.
Preparation of skin samples: A 100 mg of depilated skin sample was homogenized thor-
oughly in 2.0 ml of acetonitrile in a gentleMACS™ M tube using a gentleMACS™ Dissociator
(Miltenyi Biotec Inc., CA, USA). Each sample was subjected to three cycles of the prepro-
grammed homogenization protocol Protein_01.01 (a 55 s homogenization cycle with varying
speeds and directions of rotation). Homogenized samples were centrifuged for 10 min at 4000
rpm. Each supernatant was collected in a 4 ml glass vial and was evaporated to dryness, under
a constant flow of air, as described above. The residues were reconstituted in 100 μl acetonitrile
and were used for LC-MS analysis.
LC/MS analysis was performed with a Waters Acquity UPLC (Waters, NY, USA) equipped
with a Acquity UPLC BEH 1.7 μM C-18 column (Waters, New York, NY) interfaced to a TSQ
Quantum Access Max mass spectrometer (MS) (Thermo Fisher Scientific, Waltham, MA,
USA). The isocratic mobile phase consisted of 80% acetonitrile and 20% water, both contain-
ing 0.1% formic acid with a flow rate of 0.25 ml per minute. Under these conditions, Senicapoc
had a retention time of 0.80 minute.
Using Heated electrospray ionization source (HESI II) in positive ion mode, capillary tem-
perature 250˚C, vaporizer temperature: 30˚C, spray voltage 3500 V, sheath gas pressure (N2)
60 units, Senicapoc was analyzed by the selective reaction monitoring (SRM) transition of its
molecular ion peak 324.09 (M+1) into 228.07, 200.07,183.11 and 122.18 m/z. An 8-point cali-
bration curve from 50 nM to 10 μM concentration range was used for quantification.
Statistics
Data in text and graphs are means +/- standard error of the mean (SEM), if not stated other-
wise. If not otherwise stated, we used the unpaired Student’s T Test (two-tailed) for compari-
son of data sets. The significance level was set to a P value of<0.05.
Results
KCa3.1 induction in skin
Doxycycline(DOX)-treatment with 1 mg/ml in drinking water produced a 833-fold KCa3.1-o-
verexpression in the skin, 2310-fold KCa3.1-overexpression, particularly, in the epidermal
layer, and a 46-fold overexpressing in the intestine (Fig 1B). In bone marrow, brain, lung, skel-
etal muscle, spleen, KCa3.1-mRNA levels were similar to untreated mice.
Patch-clamp electrophysiology studies in isolated keratinocytes revealed a strong induction
of KCa3.1-function in DOX-treated KCa3.1+ mice. The KCa3.1-currents demonstrated the
typical fingerprint characteristics of KCa3.1, which were activation by 1 μM Ca2+, voltage-
independent, and mildly inwardly-rectifying. RA-2 (1 μM), a negative-gating modulator of
KCa2/3 channels [42], blocked the KCa3.1 current. KCa3.1-induction was not found in
untreated mice and KCa3.1 outward-currents were small or difficult to discriminate from
background currents in most cells (Fig 1C). In fact, we saw a clearly distinguishable KCa3.1
current in only 1 of 5 cells (S1A Fig).
We examined the KCa3.1-protein expression by immune histology (Fig 1D) and identified
immune reactivity in the thin epidermal layer of untreated mice and appreciable immune reac-
tivity in the thicker epidermal layer of DOX-treated mice (see following paragraphs).
Together, these findings demonstrate strong induction of KCa3.1-transgene expression and
function in the skin and, particularly, in the epidermis.
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Skin phenotype and behavioral alterations in DOX-treated KCa3.1+ mice
The DOX-treated KCa3.1+ mice of both sexes appeared normal during the 1st week of the
treatment and then developed progressive skin pathology with generalized piloerection,
intense scratching behavior (S Movie 1), scaly skin patches, and in some mice overt ulcerative
lesions, mainly visible in the neck areas, chest, and ears (Fig 2).
Histology (Fig 3A to 3D) of neck skin showed moderate to severe hyperplasia of the epider-
mis, affecting also the hair follicles within the dermis, and substantial hyperkeratosis. In the
epidermis of the DOX-treated mice, we found foci of moderate intra-epidermal edema (Fig
3D), similar to spongiosis, which is characteristic of eczematous dermatitis [43]. The pheno-
type was completely reversible within 6 weeks when DOX was removed after 9 days of treat-
ment (see S1B Fig).
At an earlier time point (1-week DOX), we recorded the same degree of intra-epidermal
edema and an early stage of hyperplasia and hyperkeratosis (Fig 3C and S1C Fig). Yet, at first
sight, the mice appeared healthy. Concerning controls, a 2-week DOX-treatment of the
inducer strain (R26-rtTA-M2) or of Kcnn4-transgene-harbouring mice lacking the rtTA
induced no observable skin pathology (S1D Fig).
Immune histology on KCa3.1+ skins of the neck region showed high-expression of the pro-
liferating cell nuclear antigen (PCNA), a marker of cell proliferation, in the hyperplastic epi-
dermal layer of 2-week DOX-treated mice (Fig 3E and S1E Fig). In the untreated control
Fig 2. Macroscopic skin pathology DOX-treated KCa3.1+ mice. Photographs of A) untreated Ctrl (-DOX), B) DOX-
treated KCa3.1+, C) higher magnification of the neck shown in B, D) patchy erythematous and scaly skin with
ulcerative areas of a DOX-treated mouse. Note: Videos of DOX-treated mice showing severe scratching behavior and
of Ctrls are found in the supplement.
https://doi.org/10.1371/journal.pone.0222619.g002
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animals, uniform immune reactivity was observed in the nuclei of keratinocytes lining the
basal epidermal layer. We also stained for CASP3, another marker of apoptosis, and did not
find induction of CASP3 in the hyperplastic epidermal layer or in the dermis, with the excep-
tion of ulcerative sites (S1E Fig). No CASP3 immune reactivity was seen in keratinocytes of the
epidermis of untreated controls (S1F Fig). Apoptosis as measured by TUNEL was not found at
hyperplastic sites (Fig 3F), but at wound areas with substantial tissue destruction (S1E Fig).
Together, these data demonstrate that induction of KCa3.1 produces moderate intra-der-
mal edema (sub-acute spongiosis) and drives keratinocyte proliferation, but does not cause
generalized cell toxicity and cell death. The localized epidermal damage and ulcers are likely
the result of the intense scratching behavior.
Alterations of cytokine expression profile in skin
To shed light on the mechanisms, by which KCa3.1-induction in the keratinocytes produced
spongiosis and epidermal hyperplasia, we measured the mRNA-expression of several pro-prolif-
erative cytokines that are known to promote keratinocyte proliferation in an auto-stimulatory or
autacoid fashion [44] (Fig 4). It is worth mentioning that KCa3.1-KO and/or inhibition have
been shown to reduce IL-β1 and TNFα levels in activated microglia after cerebral infarction [19].
In the skin, we found strongly increased mRNA expression of IL-β1 (60-fold), IL-6
(33-fold), and TNFα (26-fold). Expression levels of HGF and TGFα and a series of other
growth factors were not significantly altered (for more details see Fig 4A).
The induction of IL-β1 and TNFα expression was higher in the epidermal layer than in the
underlying skin tissue and the data thus demonstrate strong cytokine induction in keratino-
cytes (Fig 4B).
Systemic KCa3.1 channel blockade reduces skin pathology
We next tested whether pharmacological blockade of KCa3.1 functions can suppress this phe-
notype and treated the mice with Senicapoc-containing chow at a dose of 30mg/kg/day [45]
during the 2-weeks of DOX treatment.
The Senicapoc treatment gave rise to total plasma concentrations of 254+/-61 nM (n = 11)
and tissue levels in the skin of 2.9+/-0.9 μM (n = 4) at the time of sacrifice. At these total con-
centrations (and assuming a protein binding of 90%), pharmacological inhibition of the chan-
nel can be expected because concentrations of Senicapoc in the skin are at least 2 orders of
magnitude above the reported IC50 of 10 nM [12, 37].
As shown in Fig 5A, we report that the Senicapoc treatment did not prevent the pathologi-
cal skin alterations, but significantly reduced intra-epidermal edema by�60%, hyperplasia by
�50%, as well as a trend in reduction of hyperkeratosis and fibrosis.
Overall, this Senicapoc trial suggests that the skin pathology was caused largely by the
induced function of KCa3.1 and demonstrates that Senicapoc is able to reduce the earliest
strong alteration, i.e. intra-epidermal edema (Fig 3C and 3D), presumably by blocking
KCa.3.1-induced disturbances of epidermal water-salt homeostasis.
Considering cytokine levels in the skin (Fig 5B), Senicapoc significantly reduced mRNA-
expression levels of IL-β1 (�-88%) and of IL-6 (�-90%) when compared to DOX-treated con-
trol animals, while TNFα mRNA-expression levels were unchanged. These lower levels of pro-
proliferative cytokines could explain the lower degree of hyperplasia.
Discussion
The present study introduces a genetic model of epidermal KCa3.1-induction to investigate
the physiological and potential pathophysiological significance of this channel capable of
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controlling cell volume, growth, and cellular salt/water homeostasis in the epidermis. In fact, it
is the first study describing the consequences of genetically encoded induction of an ion chan-
nel above basal levels in the skin. Our results demonstrate that KCa3.1 over-expression was
capable of causing a severe disturbance of epidermal homeostasis.
This is based on the following lines of evidence: 1) KCa3.1-induction produced intra-epi-
dermal edema (spongiosis). 2) KCa3.1-induction produced progressive epidermal hyperplasia
and hyperkeratosis causing severe itch and ulcers. Finally, 3) KCa3.1-induction strongly up-
regulated epidermal (i.e., keratinocyte) synthesis of the pro-proliferative, auto-stimulatory,
Fig 3. Histological evaluation of skin pathology in KCa3.1+ mice. H&E-stained sections of normal skin of the neck region from an untreated mouse
(A) and a skin of the same region from a DOX-treated KCa3.1+ (B) with severe hyperplasia and hyperkeratosis. C) Summary of pathology scores. Data
are given as means +/- SEM, n = 4 (1 week DOX), n = 26 (2 weeks DOX), n = 15 (Ctrls); �P< 0.05 vs. 1 week DOX, Student’s T test. Note that the
scores for Ctrl skin are 0. D) Higher magnification of the hyperplastic epidermis of DOX-treated KCa3.1+. Note the presence of intra-epidermal
edema with enlarged intra-cellular space (indicated by white arrow). E) Immune histological stains of the proliferation marker, PCNA, in the
hyperplastic epidermis of DOX-treated KCa3.1+. Note the intense staining of the basal layer (white arrow) that becomes weaker when approaching the
stratum corneum (representative image from 3 mice). F). The TUNEL assay detected no apoptotic keratinocytes in the hyperplastic epidermis.
https://doi.org/10.1371/journal.pone.0222619.g003
Fig 4. Cytokine mRNA-expression profile. (A) Alterations of cytokine mRNA-expression profile in DOX-treated KCa3.1+ mice (DOX/-DOX). (B)
Cytokines with higher expression in the epidermis than in the underlying skin tissue (epidermis/ skin w/o epidermis). EREG, epiregulin (dox, n = 5; -DOX,
n = 5); HB-EGF, Heparin-binding EGF-like growth factor (DOX, n = 5; -DOX, n = 5); HGF, Hepatocyte growth factor (DOX, n = 5; -DOX, n = 5), Interleukin
(IL)-1β (DOX, n = 7; -DOX, n = 7), IL-6 (DOX, n = 7; -DOX, n = 7), TGFα, transforming growth factor α (DOX, n = 5; -DOX, n = 5); TNFα; tumor necrosis
factor-α (DOX, n = 5; -DOX, n = 5). Data (DOX/-DOX; Epidermis (n = 4/Skin w/o Epidermis (n = 4)) are given as means +/- SEM; �P<0.05, Student’s T test.
https://doi.org/10.1371/journal.pone.0222619.g004
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and pro-inflammatory cytokines, in particular, IL-β1, IL-6 and—by trend—TNFα. Taken
together, KCa3.1-induction in the epidermis produced skin pathology in mice that resembled
the pathological features of itchy eczematous dermatitis [43].
The physiological and pathophysiological significance of KCa3.1 in the skin has been elu-
sive until now. So far, keratinocyte KCa3.1 has been studied–superficially though—by mRNA-
expression experiments in cultured human keratinocytes [5] and immune histochemistry in
rat epidermis [39], which did not provide much information about the role of the channel in
epidermal homeostasis in-vivo. Here, we intended to provide new knowledge by generating a
murine model of genetic conditional induction of a murine KCa3.1-transgene in epidermis
(Fig 1).
The KCa3.1 induction in DOX-treated animals was highly selective for skin epidermis as
concluded from 833-fold overexpression. Concerning other tissues, we found a much less pro-
nounced 46-fold overexpression in the intestine (see below).
We confirmed KCa3.1 transgene function after in-vivo DOX-treatment by patch-clamp
electrophysiology on isolated keratinocyte, which unequivocally revealed large KCa3.1-cur-
rents being sensitive to a KCa3.1-inhibitor displaying the biophysical and pharmacological
characteristics of KCa3.1 (Fig 1C) [12]. In keratinocytes from untreated mice, KCa3.1 currents
were very small or undetectable suggesting low basal channel expression or a few KCa3.1-ex-
pressing cells. IHC demonstrated appreciable immune reactivity in the hyperplastic epidermis
of the DOX-treated mice. Immune reactivity was also found in the thin epidermis of untreated
mice, suggesting some constitutive protein expression in addition to mRNA-expression of
KCa3.1 (Fig 1D).
A major outcome of our study was that KCa3.1-induction produced visibly piloerection,
scaly skin patches, and intense scratching behavior that in turn gave rise to bloody ulcerative
lesions (Fig 2 and S1 Movie). These symptoms are similar to those of itchy eczematous derma-
titis in humans [43]. In analysis of histological sections, we observed intra-epidermal edema
(sub-acute spongiosis) and ensuing progressive hyperplasia, and hyperkeratosis as histological
features of chronic eczema [43].
It is also worth mentioning that sub-chronic conditional gene deletion of KCa3.1 in the epi-
dermis as well as life-long KCa3.1-deficiency [16] complete did not produce any skin alter-
ations, indicating that basal KCa3.1 expression is apparently not crucial for epidermal
homeostasis. In keeping with the induction of KCa3.1 in the small intestine, we also demon-
strate a mild intestinal phenotype characterized by moderate chyme accumulation and lower
propulsive spontaneous motility, which is the content of a separate report [46].
Concerning the cellular mechanisms, by which KCa3.1-induction produced this skin con-
dition, the morphological and molecular biological alterations described here agree well with
the known physiological functions of KCa3.1 [12]: 1) The intra-epidermal edema can be
explained by KCa3.1’s ability to move K+ and concomitantly water and Cl- into the extracellu-
lar compartment [13, 15, 20]. Overexpression of the channel could do this in an excessive man-
ner leading to the observed expansion of the extracellular compartment and/or cell shrinkage
producing intracellular gaps. In fact, intra-epidermal edema was already pronounced at the
early time point (1 week), when hyperplasia and hyperkeratosis was still in an initial phase.
Intra-epidermal edema was of similar grade later, when hyperplasia and hyperkeratosis
Fig 5. Senicapoc suppressed skin pathology (A) and induction of IL-1β and IL-6 in DOX-treated KCa3.1+ mice (B). Data (Senicapoc/Ctrl)
are given as means +/- SEM, n = 5 each, �P<0.05, ��P<0.01 Student’s T test. C) Examples of skin pathology in DOX-treated KCa3.1+ mice
receiving vehicle or Senicapoc. Inserts: 2.7-digital zoom-into epidermis showing lower grade of intra-epidermal edema in Senicapoc-treated
mice.
https://doi.org/10.1371/journal.pone.0222619.g005
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progressed further. Therefore, intra-epidermal edema can be considered the starting point for
the latter alterations.
2) In addition to its function as a K+ secreting channel, KCa3.1 activity is known to produce
strong membrane hyperpolarization, which in turn potentiates calcium-influx enabling long-
lasting elevations in [Ca2+]I (for review see: [1, 36]). In several cell systems, this elevation of
[Ca2+]I has been shown to be required for the sustained initiation of several cellular processes,
including proliferation and migration [1, 47]. KCa3.1-mediated hyperpolarization and ensuing
amplification of [Ca2+]I signaling is known to regulate cytokine production in T cells, activated
fibroblasts or smooth muscle cells (for review see: [1]). Accordingly, inhibition or genetic
knockdown of the channel has been reported to reduce IL-2 production by T cells [47,48] and
IL-β1 and TNFα levels by microglia in ischemic stroke [19]. Here, we showed that the reverse
maneuver (induction) resulted in a higher expression of IL-β1 and–by trend- TNFα in kerati-
nocytes of the epidermis (Fig 5). This keratinocyte cytokine production may drive hyperplasia
and hyperkeratosis in an auto-stimulatory fashion.
Considering the impressive magnitude of hyperplasia and hyperkeratosis (Fig 3), we specu-
late that this is a secondary and overshooting repair mechanism in response to intra-epidermal
edema and epidermal destabilization.
In summary, we provide first mechanistic evidence that KCa3.1 induction produced skin
pathology in-vivo by causing extracellular fluid accumulation and epidermal destabilization as
a primary event and secondary phenotypic switch to a proliferative keratinocyte phenotype
(PCNA-high, Fig 3E), producing epidermal hyperplasia.
It is worth mentioning that the selective KCa3.1-blocker Senicapoc significantly prevented
both the primary intra-epidermal edema and the subsequent hyperplasia (Fig 5). The preven-
tion of edema is somewhat reminiscent of the reported reduction in in-vitro cyst formation by
kidney cells from patients with autosomal-dominant polycystic kidney disease with a KCa3.1
blocker [25]. Moreover, Senicapoc treatment lessened increases of IL-β1 and IL-6 mRNA-
expression levels in the affected skin (Fig 5). These data strongly suggest that these morpholog-
ical alterations and the higher expression of pro-proliferative cytokines are mediated by
KCa3.1 channel function, and likely act as mechanistic drivers of epidermal hyperplasia.
Because the treatment did not fully suppress the phenotype, we cannot fully exclude additional
local or systemic mechanisms.
There are some limitations applying to this study: While the qRT-PCR quantification of
KCa3.1-transgene induction in the skin and the epidermis is clear-cut by showing expression
levels several thousand times above basal level, protein levels were not proven by Western-
blotting because of an lack of specificity of currently available lots of KCa3.1-Ab. Yet, trans-
gene function was verified by patch-clamp electrophysiology showing clear-cut KCa3.1 func-
tions in keratinocyte that far larger than in keratinocyte, in which the channel has not been
induced. The skin phenotype characterized by epidermal spongiosis, hyperplasia, hyperkerato-
sis causing visible skin alterations and itch is solid and reproducible and we provide evidence
that this phenotype is caused by channel functions since a selective channel prevents to a con-
siderable extent this phenotype. The changes in the skin cytokine expression profile shows
clear increases IL-1β and IL-6, pointing to the contribution of these cytokines to the develop-
ment of this phenotype. Yet, we are aware of the expectantly high physiological complexity
when studying an in-vivo model and, for instance, do not wish to exclude additional systemic
mechanisms, e.g. a contribution of the immune system.
Despite these limitations, it is still worth mentioning that compared with human skin dis-
eases, the skin phenotype in KCa3.1+ mice share similarities with human eczematous dermati-
tis characterized by spongiosis, epidermal hyperplasia, and itch, as important pathological
features [43]. Yet, the cellular mechanisms causing this condition and, particularly, spongiosis
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are poorly understood. In this regard, it is tempting to speculate that epidermal KCa3.1 could
also be a mechanistic player in human skin disease. Yet, at present a pathomechanistic role of
KCa3.1 has not been shown for human skin conditions with the exception of role in melanoma
cell proliferation. Still, our study provides the rationale to investigate KCa3.1-function in spe-
cifically eczematous dermatitis with keratinocyte hyperplasia and in other skin pathologies,
characterized by excessive keratinocyte growth such as psoriasis, and test clinical efficacy of
KCa3.1-inhibitors.
In conclusion, epidermal KCa3.1 overexpression in murine skin produces itchy eczematous
dermatitis. This can be dampened by pharmacological channel inhibition. Future target identi-
fication and validation studies in patients will show whether KCa3.1-inhibitors are of thera-








S1 Movie. Supplemental Media file 1; Description: Two sequences showing mice treated
with DOX for two weeks and a sequence showing control mice receiving only sucrose. Of
the last two sequences, the first shows a mouse from the Senicapoc trial that did not receive
Senicapoc. The second sequence shows a mouse that received Senicapoc.
(MP4)
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